{
    "root": "30387bb7-762a-175d-e063-6394a90a5ccf",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Cefdinir",
    "value": "20250313",
    "ingredients": [
        {
            "name": "CARBOXYMETHYLCELLULOSE CALCIUM",
            "code": "UTY7PDF93L"
        },
        {
            "name": "POLYOXYL 40 STEARATE",
            "code": "13A4J4NH9I"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "CEFDINIR",
            "code": "CI0FAO63WC"
        }
    ],
    "indications": "To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir capsules and other antibacterial drugs, cefdinir capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.\n                  \n                  Cefdinir capsules are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below.\n                  \n                      \n                  \n                  \n                     Adults and Adolescents\n                  \n                  \n                      \n                  \n                  Community-Acquired Pneumonia\n                  \n                  Caused by\n \n  Haemophilus influenzae(including β-lactamase producing strains),\n \n  Haemophilus parainfluenzae(including β-lactamase producing strains),\n \n  Streptococcus pneumoniae(penicillin-susceptible strains only), and\n \n  Moraxella catarrhalis(including β-lactamase producing strains) (see\n \n  \n                        CLINICAL STUDIES\n                     ).\n\n \n                  \n                  Acute Exacerbations of Chronic Bronchitis\n                  \n                  Caused by\n \n  Haemophilus influenzae(including β-lactamase producing strains),\n \n  Haemophilus parainfluenzae(including β-lactamase producing strains),\n \n  Streptococcus pneumoniae(penicillin-susceptible strains only), and\n \n  Moraxella catarrhalis(including β-lactamase producing strains).\n\n \n                  \n                  Acute Maxillary Sinusitis\n                  \n                  Caused by\n \n  Haemophilus influenzae(including β-lactamase producing strains),\n \n  Streptococcus pneumoniae (penicillin-susceptible strains only), and\n \n  Moraxella catarrhalis(including β-lactamase producing strains).\n\n \n                  \n                  \n                     NOTE:For information on use in pediatric patients, see\n \n  \n                        Pediatric Use \n \n  and\n \n  \n                        DOSAGE AND ADMINISTRATION\n                     .\n\n \n                  \n                      \n                  \n                  Pharyngitis/Tonsillitis\n                  \n                  Caused by\n \n  \n                        Streptococcus pyogenes\n                     (see\n \n  CLINICAL STUDIES).\n\n \n                  \n                  \n                     NOTE:Cefdinir is effective in the eradication of\n \n  S. pyogenesfrom the oropharynx. Cefdinir has not, however, been studied for the prevention of rheumatic fever following\n \n  S. pyogenespharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever.\n\n \n                  \n                  Uncomplicated Skin and Skin Structure Infections\n                  Caused by\n \n  Staphylococcus aureus(including β-lactamase producing strains) and\n \n  Streptococcus pyogenes.\n\n \n                  \n                      \n                  \n                  \n                     Pediatric Patients\n                  \n                  \n                      \n                  \n                  Acute Bacterial Otitis Media\n                  \n                  Caused by\n \n  Haemophilus influenzae(including β-lactamase producing strains),\n \n  Streptococcus pneumoniae (penicillin-susceptible strains only), and\n \n  Moraxella catarrhalis(including β-lactamase producing strains).\n\n \n                  \n                  Pharyngitis/Tonsillitis\n                  \n                  Caused by\n \n  Streptococcus pyogenes(see\n \n  \n                        CLINICAL STUDIES\n                     ).\n\n \n                  \n                      \n                  \n                  \n                     NOTE:Cefdinir is effective in the eradication of\n \n  S. pyogenesfrom the oropharynx. Cefdinir has not, however, been studied for the prevention of rheumatic fever following\n \n  S. pyogenespharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever.\n\n \n                  \n                  Uncomplicated Skin and Skin Structure Infections\n                  \n                  Caused by\n \n  Staphylococcus aureus(including β-lactamase producing strains) and\n \n  Streptococcus pyogenes.",
    "contraindications": "(see\n \n  INDICATIONS AND USAGEfor Indicated Pathogens) \n     The recommended dosage and duration of treatment for infections in adults and adolescents are described in the following chart; the total daily dose for all infections is 600 mg. Once-daily dosing for 10 days is as effective as b.i.d. dosing. Once-daily dosing has not been studied in pneumonia or skin infections; therefore, cefdinir capsules should be administered twice daily in these infections. Cefdinir capsules may be taken without regard to meals. \n     Adults and Adolescents (Age 13 Years and Older) \n  \n                  \n                  \n                     \n                     \n                     \n                     \n                        \n                           Type of Infection \n     \n                           \n                           Dosage \n     \n                           \n                           Duration \n     \n                           \n                        \n                        \n                           Community-Acquired Pneumonia \n     \n                           \n                           300 mg q12h \n     \n                           \n                           10 days \n     \n                           \n                        \n                        \n                           Acute Exacerbations of Chronic \n       Bronchitis \n     \n                           \n                           300 mg q12h \n       or \n       600 mg q24h \n     \n                           \n                           5 to 10 days \n       10 days \n     \n                           \n                        \n                        \n                           Acute Maxillary Sinusitis \n     \n                           \n                           300 mg q12h \n       or \n       600 mg q24h \n     \n                           \n                           10 days \n       10 days \n     \n                           \n                        \n                        \n                           Pharyngitis/Tonsillitis \n     \n                           \n                           300 mg q12h \n       or \n       600 mg q24h \n     \n                           \n                           5 to 10 days \n       10 days \n     \n                           \n                        \n                        \n                           Uncomplicated Skin and Skin Structure Infections \n     \n                           \n                           300 mg q12h \n     \n                           \n                           10 days \n     \n                           \n                        \n                     \n                  \n                  \n                     Patients with Renal Insufficiency\n                  \n                  For adult patients with creatinine clearance < 30 mL/min, the dose of cefdinir should be 300 mg given once daily. \n    Creatinine clearance is difficult to measure in outpatients. However, the following formula may be used to estimate creatinine clearance (CL\n \n  cr) in adult patients. For estimates to be valid, serum creatinine levels should reflect steady-state levels of renal function. \n  \n                  \n                  \n                     \n                     \n                     \n                     \n                        \n                           Males: \n     \n                           \n                           CL\n    \n     cr= \n     \n                           \n                           (weight) (140–age) \n     \n                           \n                        \n                        \n                           (72) (serum creatinine) \n     \n                           \n                        \n                        \n                           Females: \n     \n                           \n                           CL\n    \n     cr= \n     \n                           \n                           0 .8 5 x above value \n     \n                           \n                        \n                        \n                           where creatinine clearance is in mL/min, age is in years, weight is in kilograms, and serum creatinine is in mg/dL.\n    \n     1\n                              \n                           \n                        \n                     \n                  \n                   The following formula may be used to estimate creatinine clearance in pediatric patients: \n  \n                  \n                  \n                     \n                     \n                     \n                        \n                           CL\n    \n     cr= K x \n     \n                           \n                           body length or height \n     \n                           \n                        \n                        \n                           serum creatinine \n     \n                           \n                        \n                        \n                           where K=0.55 for pediatric patients older than 1 year\n    \n     2and 0.45 for infants (up to 1 year).\n    \n     3\n                              \n                           \n                        \n                     \n                  \n                   In the above equation, creatinine clearance is in mL/min/1.73 m\n \n  2, body length or height is in centimeters, and serum creatinine is in mg/dL.\n\n \n                   For pediatric patients with a creatinine clearance of < 30 mL/min/1.73 m\n \n  2, the dose of cefdinir should be 7 mg/kg (up to 300 mg) given once daily. \n  \n                     Patients on Hemodialysis \n   \n                     Hemodialysis removes cefdinir from the body. In patients maintained on chronic hemodialysis, the recommended initial dosage regimen is a 300 mg or 7 mg/kg dose every other day. At the conclusion of each hemodialysis session, 300 mg (or 7 mg/kg) should be given. Subsequent doses (300 mg or 7 mg/kg) are then administered every other day.",
    "warningsAndPrecautions": "Cefdinir capsules, USP containing 300 mg cefdinir, having off white to light yellow colour granular powder filled in size “0” hard gelatin capsules, blue opaque cap imprinted “A041” with black ink and blue opaque body imprinted “300” with black ink and are supplied as follows:\n                  \n                  \n                  NDC: 70518-4169-00\n                  NDC: 70518-4169-01\n                  NDC: 70518-4169-02\n                  \n                  PACKAGING: 20 in 1 BOTTLE PLASTIC\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  PACKAGING: 14 in 1 BOTTLE PLASTIC \n                  \n                  \n                  \n                  Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].\n                  \n                  \n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions": "Cefdinir is contraindicated in patients with known allergy to the cephalosporin class of antibiotics."
}